Who are mometasone furoate + Oxymetazoline's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mometasone-furoate-oxymetazoline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

mometasone furoate + Oxymetazoline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mometasone furoate + Oxymetazoline (mometasone furoate + Oxymetazoline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intranasal corticosteroid + nasal decongestant combination. Area: Otolaryngology / Rhinology.

marketed Intranasal corticosteroid + nasal decongestant combination Glucocorticoid receptor (mometasone); alpha-2 adrenergic receptor (oxymetazoline) Otolaryngology / Rhinology Small molecule Live · refreshed every 30 min

Target snapshot

mometasone furoate + Oxymetazoline (mometasone furoate + Oxymetazoline) — Guangzhou Women and Children's Medical Center. Mometasone furoate reduces nasal inflammation via glucocorticoid receptor activation, while oxymetazoline constricts nasal blood vessels to reduce congestion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mometasone furoate + Oxymetazoline TARGET	mometasone furoate + Oxymetazoline	Guangzhou Women and Children's Medical Center	marketed	Intranasal corticosteroid + nasal decongestant combination	Glucocorticoid receptor (mometasone); alpha-2 adrenergic receptor (oxymetazoline)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intranasal corticosteroid + nasal decongestant combination class)

Guangzhou Women and Children's Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mometasone furoate + Oxymetazoline — Competitive Intelligence Brief. https://druglandscape.com/ci/mometasone-furoate-oxymetazoline. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab